Compare
Sagimet Biosciences Inc. vs Avalo Therapeutics, Inc. vs PMV Pharmaceuticals, Inc. vs Aardvark Therapeutics, Inc.
| Latest fiscal year | Sagimet Biosciences Inc. SGMT | Avalo Therapeutics, Inc. AVTX | PMV Pharmaceuticals, Inc. PMVP | Aardvark Therapeutics, Inc. AARD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $59.0K | n/a | $0 |
| Revenue growth (YoY) | n/a | -86.6% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$51.04M | -$78.26M | -$77.74M | -$57.59M |
| EPS (Diluted) | -$1.58 | -$5.84 | -$1.48 | -$2.93 |
| Operating cash flow | -$45.65M | -$51.46M | -$73.58M | -$54.17M |
| Free cash flow | n/a | n/a | -$73.61M | -$54.27M |
| Cash & equivalents | $35.02M | $15.86M | $37.98M | $47.05M |
| Total assets | $116.48M | $116.46M | $116.56M | $117.18M |
| Total liabilities | n/a | $33.41M | $11.85M | $10.55M |
| Shareholders' equity | $111.38M | $83.05M | $104.71M | $106.63M |
| Return on year-end equity | -45.8% | -94.2% | -74.2% | -54.0% |
| Shares outstanding | n/a | 18.51M | 53.33M | 21.82M |
Revenue, most recent five fiscal years
| Fiscal year | Sagimet Biosciences Inc. | Avalo Therapeutics, Inc. | PMV Pharmaceuticals, Inc. | Aardvark Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $2.00M Ended 2023-12-31 | $59.0K Ended 2025-12-31 | n/a | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $441.0K Ended 2024-12-31 | n/a | n/a |
| 2 years earlier | n/a | $1.92M Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $18.05M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $5.40M Ended 2021-12-31 | n/a | n/a |